Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, multi-regional, multi-center, double-blind, placebo-controlled Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of VistaGen's PH94B (referred to by AffaMed as AM005) for the acute treatment of anxiety in adults with social anxiety disorder (SAD)

Next Previous
Search
Trial Profile

A randomized, multi-regional, multi-center, double-blind, placebo-controlled Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of VistaGen's PH94B (referred to by AffaMed as AM005) for the acute treatment of anxiety in adults with social anxiety disorder (SAD)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fasedienol (Primary)
  • Indications Anxiety; Social phobia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PALISADE Global

    • Most Recent Events

    • 18 Apr 2022 New trial record
    • 12 Apr 2022 According to VistaGens Therapeutics media release, the company is looking forward to dosing participants in this trial later this year, topline results from this trial is anticipated in mid-2024; Michael Liebowitz, M.D. will serve as the principal investigator.
    • 12 Apr 2022 According to VistaGens Therapeutics media release, PALISADE Global is a study separate from PALISADE-1 and PALISADE-2, which are currently underway and designed to support VistaGens PH94B New Drug Application (NDA) submission to the FDA, should the studies be successful; this trial is designed to support commercialization of PH94B in China and other markets outside the U.S; the companies also anticipate initiating this Phase 3 study in Canada, Mexico, and South Korea.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top